{"id":"https://openalex.org/W2979786708","doi":"https://doi.org/10.1182/blood.v110.11.1036.1036","title":"Importance of Early Intervention with Dasatinib at Cytogenetic Rather Than Hematologic Resistance to Imatinib.","display_name":"Importance of Early Intervention with Dasatinib at Cytogenetic Rather Than Hematologic Resistance to Imatinib.","publication_year":2007,"publication_date":"2007-11-16","ids":{"openalex":"https://openalex.org/W2979786708","doi":"https://doi.org/10.1182/blood.v110.11.1036.1036","mag":"2979786708"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v110.11.1036.1036","doi":"https://doi.org/10.1182/blood.v110.11.1036.1036","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v110.11.1036.1036","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop M. Kantarjian","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019337932","display_name":"Alfonso Quint\u00e1s\u2010Cardama","orcid":"https://orcid.org/0000-0002-4240-9846","observed_orcids":["https://orcid.org/0000-0002-4240-9846"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Alfonso Quintas-Cardama","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102743501","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0003-3386-6540","observed_orcids":["https://orcid.org/0000-0003-3386-6540"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Susan O\u2019Brien","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000750846","display_name":"Farhad Ravandi","orcid":"https://orcid.org/0000-0002-7621-377X","observed_orcids":["https://orcid.org/0000-0002-7621-377X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farhad Ravandi","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055045706","display_name":"Gautam M. Borthakur","orcid":"https://orcid.org/0000-0001-7679-6453","observed_orcids":["https://orcid.org/0000-0001-7679-6453"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gautam Borthakur","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David Liu","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033937088","display_name":"Tai\u2010Tsang Chen","orcid":"https://orcid.org/0000-0003-2524-0409","observed_orcids":["https://orcid.org/0000-0003-2524-0409"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Tai-Tsang Chen","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015101485","display_name":"J\u00f6rge E. Cortes","orcid":"https://orcid.org/0000-0002-8636-1071","observed_orcids":["https://orcid.org/0000-0002-8636-1071"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jorge Cortes","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5019337932","https://openalex.org/A5033937088","https://openalex.org/A5102743501"],"corresponding_institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210091812"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":1.4276,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.83407498,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"110","issue":"11","first_page":"1036","last_page":"1036"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-phase-cml","display_name":"chronic phase CML","score":0.921999990940094},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9139999747276306},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.9940000176429749},{"id":"https://openalex.org/keywords/cytogenetic-response","display_name":"cytogenetic response","score":0.8159999847412109},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.8999999761581421},{"id":"https://openalex.org/keywords/complete-cytogenetic-response","display_name":"complete cytogenetic response","score":0.8330000042915344},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.722000002861023},{"id":"https://openalex.org/keywords/second-generation-tyrosine-kinase-inhibitors","display_name":"second-generation tyrosine kinase inhibitors","score":0.8550000190734863},{"id":"https://openalex.org/keywords/early-intervention","display_name":"early intervention","score":0.6320000290870667},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7979999780654907}],"concepts":[{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9022043943405151},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.8190513849258423},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7480939626693726},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7103497385978699},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.5633164644241333},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4944765567779541},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.43694016337394714},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4271264672279358},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.09881296753883362},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v110.11.1036.1036","doi":"https://doi.org/10.1182/blood.v110.11.1036.1036","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v110.11.1036.1036","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2022158208","https://openalex.org/W2080125373","https://openalex.org/W2004492241","https://openalex.org/W32983286","https://openalex.org/W2552412286","https://openalex.org/W2588521824","https://openalex.org/W2561844337","https://openalex.org/W2991771265","https://openalex.org/W2242087004","https://openalex.org/W2127133818"],"abstract_inverted_index":{"Abstract":[0],"Recent":[1],"data":[2,128],"for":[3,39,43,48,69,75,110,212,226,433,445],"patients":[4,111,187,213,237,252,293,446],"with":[5,29,60,71,77,100,108,188,191,199,228,238,245,253,275,294],"chronic-phase":[6,40,72],"(CP)":[7],"CML":[8,73,190],"indicate":[9],"that":[10,58],"development":[11,82,135,154],"of":[12,37,83,87,105,117,125,136,145,155,234,247,260,266,272,278,281,292,423,426,438,458],"resistance":[13,85,115,138,192,221,240,268],"or":[14,218,299],"intolerance":[15],"to":[16,23,131,139,148,152,193,222,241,251,429,447,453],"imatinib":[17,140,195,224,242,267,439],"and":[18,46,173,269,419,431],"treatment":[19,427],"intervention":[20,59,262,435],"following":[21],"progression":[22,301],"advanced-phase":[24,78],"disease":[25],"are":[26],"both":[27],"associated":[28,244],"poor":[30,146],"clinical":[31,163],"outcome":[32],"(with":[33],"3-year":[34,102],"survival":[35,103,249,358],"rates":[36,209,233],"72%":[38],"disease,":[41],"30%":[42],"accelerated-phase":[44],"CML,":[45],"7%":[47],"blast-phase":[49],"CML)":[50],"(Kantarjian":[51],"et":[52],"al.":[53],"Cancer2007;109:1556\u201360).":[54],"Results":[55],"also":[56],"demonstrate":[57],"a":[61,88,101,118,143,449],"second-generation":[62],"tyrosine":[63],"kinase":[64],"inhibitor":[65],"is":[66],"more":[67],"effective":[68],"individuals":[70],"than":[74,225],"those":[76,227],"disease.":[79],"Of":[80],"note,":[81],"hematologic":[84,90,137,229,254,450],"(loss":[86],"complete":[89,205,296],"response":[91,121,147,207,298,304,428],"[CHR])":[92],"was":[93,130],"identified":[94],"as":[95],"an":[96],"independent":[97],"prognostic":[98],"factor":[99],"rate":[104],"57%":[106],"(compared":[107],"92%":[109],"who":[112,214],"experienced":[113],"cytogenetic":[114,120,156,206,220,239,297,303],"[loss":[116],"major":[119],"(MCyR)]).":[122],"The":[123,231],"objective":[124],"the":[126,134,153,258,264,270,421,456],"current":[127],"analysis":[129],"assess":[132],"whether":[133],"would":[141],"be":[142],"predictor":[144],"dasatinib":[149,162],"(SPRYCEL\u00ae)":[150],"relative":[151],"resistance.":[157,230,440],"Data":[158],"from":[159],"three":[160],"Phase-II/III":[161],"studies":[164],"(CA180\u2013013":[165],"[70":[166,170],"mg":[167,171,178,181,184,322,331,340,349,379,388,397,406],"BID],":[168,172],"CA180\u2013017":[169,313,370],"CA180\u2013034":[174,320,377],"[100mg":[175],"QD,":[176,182],"50":[177,330,344,347,387],"BID,":[179],"140":[180,339,396],"70":[183,348,405],"BID])":[185],"in":[186,236,263,436],"CP":[189],"prior":[194,223],"were":[196,210,243],"evaluated.":[197],"Consistent":[198],"our":[200],"earlier":[201],"findings,":[202],"significantly":[203,454],"higher":[204],"(CCyR)":[208],"reported":[211],"had":[215],"developed":[216],"secondary":[217],"acquried":[219],"improved":[232],"CCyR":[235,274],"prolongation":[246],"progression-free":[248],"compared":[250],"resistance,":[255],"thereby":[256],"confirming":[257],"importance":[259,422],"early":[261,434],"event":[265],"significance":[271],"achieving":[273],"dasatinib.":[276,459],"Loss":[277,280],"MCyR":[279],"CHR":[282],"N":[283,286],"n":[284,287,289],"%":[285,288],"=":[290],"number":[291],"[1]":[295,305],"[2]":[300,362],"Complete":[302],"CA180\u2013013":[306,363],"47":[307,364],"34":[308],"72":[309],"71":[310,367],"27":[311],"38":[312],"19":[314,352,371],"12":[315,336,354,393,411],"63":[316],"22":[317,374],"5":[318],"23":[319,351,408],"100":[321,378,392],"QD":[323,341,380,398],"28":[324,381],"21":[325],"75":[326],"14":[327,329,384],"2":[328,355,400,403,409],"BID":[332,350,389,407],"17":[333,356,390],"11":[334],"65":[335],"3":[337,365,375],"25":[338],"18":[342,399],"9":[343],"16":[345,402],"8":[346],"83":[353],"Progression-free":[357],"at":[359],"1":[360,372,382,385],"year":[361],"95":[366,410],"15":[368],"84":[369],"94":[373],"85":[376],"96":[383],"93":[386,404],"0":[391],"6":[394],"58":[395],"87":[401],"4":[412],"69":[413],"These":[414],"results":[415],"confirm":[416],"previous":[417],"observations":[418],"emphasize":[420],"close":[424],"monitoring":[425],"imatinib,":[430],"argue":[432],"case":[437],"Late":[441],"intervention,":[442],"ie":[443],"waiting":[444],"lose":[448],"response,":[451],"appears":[452],"diminish":[455],"effectiveness":[457]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-10-18T00:00:00"}